Targeting the EGFR-family for therapy: biological challenges and clinical perspective

Patel, R. and Leung, H.Y. (2012) Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Current Pharmaceutical Design, 18(19), pp. 2672-2679.

Full text not currently available from Enlighten.


Members of epidermal growth factor receptor (EGFR) or ErbB receptor family play a critical role in a wide range of human cancers. In the past decade, there has been a remarkable progress in the ErbB targeted therapeutics. However, a substantial portion of patients have non-responsive disease or show evidence of tumour relapse following initial success with anti-ErbB agents. Improved insights into the functioning of ErbB receptor family have led to additional second and third generation active anti-ErbB therapies. In this review, we will summary salient features of the ErbB receptor physiology and mechanism involved in abnormal ErbB signalling in tumours. The rationale of anti-ErbB receptor therapies are outlined along with key mechanisms proposed for resistance to treatment. We will also summarise the current model for combined anti-ErbB therapies. In conclusion, increased understanding of the molecular pathways that confer resistance to anti-ErbB therapeutics will be essential in minimising tumour resistance to ErbB targeted treatments.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Leung, Professor Hing and Patel, Dr Rachana
Authors: Patel, R., and Leung, H.Y.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Current Pharmaceutical Design
ISSN (Online):1873-4286
Published Online:28 February 2012

University Staff: Request a correction | Enlighten Editors: Update this record